Methanone, ((3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl)((3R,5S)-4-hydroxy-3,5-dimethyl-4-phenyl-1-piperidinyl)- | 862281-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Methanone, ((3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl)((3R,5S)-4-hydroxy-3,5-dimethyl-4-phenyl-1-piperidinyl)-
• 英文别名: [(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]-[(3S,5R)-4-hydroxy-3,5-dimethyl-4-phenylpiperidin-1-yl]methanone
• CAS: 862281-92-3
• 化学式: C₂₈H₃₆F₂N₂O₂
• 分子量: 470.6
• InChiKey: WHPJOAUPIZDJNX-YTEQHECZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pharmaceutically active compounds
  申请人：Calabrese Antony Andrew

  公开号：US20050176772A1

  公开（公告）日：2005-08-11

  The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

  本发明涉及一类通式（I）所示的黑素皮质素MCR4激动剂，其中R1、R2、R3、R4和R5如本文所定义，特别涉及选择性MCR4激动剂化合物，它们在医学上的应用，含有它们的组合物，用于它们制备的工艺以及用于这些工艺的中间体。
• Use of Mc4 Receptor Agonist Compounds
  申请人：McMurray Gordon

  公开号：US20080234280A1

  公开（公告）日：2008-09-25

  This invention relates to the use of an MC4 receptor agonist compound for the manufacture of a medicament for the treatment of lower urinary tract dysfunction.

  该发明涉及使用MC4受体激动剂化合物制造治疗下尿路功能障碍的药物。
• PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS
  申请人：Pfizer Limited

  公开号：EP1716135A1

  公开（公告）日：2006-11-02
• MC4R-AGONISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION
  申请人：Pfizer Limited

  公开号：EP1928460A2

  公开（公告）日：2008-06-11
• POSITIVE ALLOSTERIC MODULATORS OF THE GLP-1 RECEPTOR
  申请人：Vanderbilt University

  公开号：US20190010162A1

  公开（公告）日：2019-01-10

  Described are positive allosteric modulators of the GLP-1 receptor, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for diabetes mellitus type 2, obesity, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, cognitive dysfunction, learning disability, and asthma in a subject.